Cannabis Sativa Derived Formulation for Transmucosal and Transdermal Delivery
A Cannabis sativa -derived formulation for transmucosal and transdermal delivery is disclosed comprising Cannabis sativa -derived compounds nanoencapsulated in phospholipid-based vesicles. A method of encapsulating cannabis -derived compounds in nanosized phospholipid vesicles is also disclosed. Cannabis sativa -derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids. Also disclosed herein are methods of transmucosal and transdermal administration of the formulation having phospholipid vesicles with nanoencapsulated Cannabis sativa -derived substances.
1 . A composition comprising: one or more Cannabis sativa -derived substances nanoencapsulated in phospholipid vesicles having phospholipids, ethanol and water, wherein phosphatidylcholine comprises at least 50% by weight of the phospholipids in the phospholipid vesicles; said Cannabis sativa -derived substances being selected from cannabidiol (CBD), tetrahydrocannabinol (THC), Cannabis sativa -derived terpenes, Cannabis sativa -derived flavonoids, a whole plant extract of Cannabis sativa , and combinations thereof.
2 . The composition of claim 1 , wherein the concentration of Cannabis sativa -derived substance encapsulated in the phospholipid vesicles is from 0.01% to 1.0% w/w.
3 . The composition of claim 1 , wherein the phospholipid vesicles having the encapsulated Cannabis sativa -derived substance are sized from 25 nm to 200 nm.
4 . The composition of claim 1 , wherein the Cannabis sativa -derived substance is cannabidiol (CBD).
5 . The composition of claim 1 , wherein the Cannabis sativa -derived substance is tetrahydrocannabinol (THC).
6 . The composition of claim 1 , wherein the Cannabis sativa -derived substance is a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC).
7 . The composition of claim 1 , wherein the Cannabis sativa -derived substance is a whole plant extract of Cannabis sativa.
8 . The composition of claim 1 , wherein the composition is formulated for transmucosal or transdermal administration.
9 . A composition comprising one or more Cannabis sativa -derived substances nanoencapsulated in phospholipid vesicles sized from 25 nm to 200 nm, said phospholipid vesicles comprising phospholipids, ethanol and water; said Cannabis sativa -derived substances being selected from cannabidiol (CBD), tetrahydrocannabinol (THC), Cannabis sativa -derived terpenes, Cannabis sativa -derived flavonoids, a whole plant extract of Cannabis sativa , and combinations thereof.
10 . The composition of claim 9 , wherein the concentration of Cannabis sativa -derived substance encapsulated in the phospholipid vesicles is from 0.01% to 1.0% w/w.
11 . The composition of claim 9 , wherein the phospholipids in the phospholipid vesicles have at least 50% phosphatidylcholine by weight.
12 . The composition of claim 9 , wherein the Cannabis sativa -derived substance is cannabidiol (CBD).
13 . The composition of claim 9 , wherein the Cannabis sativa -derived substance is tetrahydrocannabinol (THC).
14 . The composition of claim 9 , wherein the Cannabis sativa -derived substance is a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC).
15 . The composition of claim 9 , wherein the Cannabis sativa -derived substance is a whole plant extract of Cannabis sativa.
16 . The composition of claim 9 , wherein said phospholipid vesicles with the nanoencapsulated Cannabis sativa -derived substance are administered to the oral cavity of a subject for transmucosal uptake of the Cannabis sativa -derived substance.
17 . A composition comprising one or more Cannabis sativa -derived substance nanoencapsulated in phospholipid vesicles sized from 25 nm to 200 nm, said Cannabis sativa -derived substance concentration is from 0.01% to 1.0% w/w, and said phospholipid vesicles comprising phospholipids, ethanol and water.
18 . The composition of claim 17 , wherein the Cannabis sativa -derived substance is selected from cannabidiol (CBD), tetrahydrocannabinol (THC), Cannabis sativa -derived terpenes, Cannabis sativa -derived flavonoids, a whole plant extract of Cannabis sativa , and combinations thereof.
19 . The composition of claim 17 , wherein the phospholipids in the phospholipid vesicles have at least 50% phosphatidylcholine by weight.
20 . The composition of claim 17 , wherein the Cannabis sativa -derived substance is cannabidiol (CBD).